Role of cardiac magnetic resonance in evaluation of pulmonary hypertension

doi:10.3877/cma.j.issn.1674-6902.2019.03.008

Abstract

Abstract:

Objective

To study the role of cardiac magnetic resonance in the evaluation of pulmonary hypertension.

Methods

From June 2012 to October 2018, 25 patients with pulmonary hypertension who were admitted to the General Hospital of Xinjiang Military Command, Urumqi, China, and were able to tolerate the right heart floating catheter examination were selected for this study. Each patient was subjected to a right heart floating catheter examination and a heart magnetic resonance examination. The related indicators of the right heart floating catheter examination and cardiac magnetic resonance examination were measured respectively and the relevance was analyzed.

Results

In order to eliminate the influence of individual differences on the anatomical data, the inner diameter of the pulmonary trunk, the inner diameter of the right pulmonary trunk and the thickness of the anterior wall of the right ventricle measured by magnetic resonance imaging (MRI) were compared with the transverse diameter of the right diaphragm top plane. The results of one-way analysis of variance (ANOVA) showed that there existed significant differences between the inner diameter of the pulmonary trunk/the transverse diameter of the right diaphragm top plane (MPA/T), the inner diameter of the right pulmonary trunk/the transverse diameter of the right diaphragm top plane (RAP), and the thickness of the anterior wall of the right ventricle/the transverse diameter of the right diaphragm top plane (RVW/T) between the experimental group and the control group (P<0.05). There were significant differences in the pulmonary arterial systolic pressure (PASP), the pulmonary arterial mean pressure (PAMP) and the pulmonary vascular resistance (PVR) between the experimental group and the control group (P<0.05). The correlation analysis of the anatomical indexes, MPA/T, RAP/T, RVW/T, and PASP, PAMP and PVR showed that except for RAP/T and PVR (P>0.01), the P values of the rest indicators were less than 0.01, indicating that MPA/T and RAP/T were positively correlated with PASP, PAMP and PVR, and RVW/T was positively correlated with PASP and PAMP.

Conclusion

The anatomical indexes, MPA/T, RAP/T, and RVW/T, obtained from cardiac magnetic resonance examination, can be used to evaluate the presence or absence of pulmonary arterial hypertension and assess the degree of pulmonary arterial hypertension, it has important clinical significance.

Key words: Pulmonary hypertension, Right heart floating catheter examination, Cardiac magnetic resonance, Clinical significance

chuanzi Zhang, peng Jiang, feng Zhang. Role of cardiac magnetic resonance in evaluation of pulmonary hypertension[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2019, 12(03): 306-310.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2019.03.008

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2019/V12/I03/306

Figures/Tables 4

References 32

1	Kiely DG, Elliot CA, Sabroe I, et al. Pulmonary bypertension：diagnosis and management[M]//.Diagnosis and Management of Pulmonary Hypertension. New York: Springer, 2013: 953-958.
2	徐楠，吴伟春，牛丽莉，等. 肺动脉高压患者心室重构的超声心动图指标与肺阻力的相关性研究[J]. 中国循环杂志，2017, 32(2): 161-164.
3	胡海燕，张静芳，韩秀清. 超声心动图对新生儿肺动脉高压的诊断价值[J]. 安徽医学，2016, 37(5): 590-592.
4	Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model[J]. Eur Respir J, 2017, 50: 1700740.
5	McLaughlin VV, Hoeper MM, Channick RN, et al. Pulmonary arterial hypertension-related morbidity is prognostic for mortality[J]. J Am Coll Cardiol, 2018, 71: 752-763.
6	Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension[J]. Eur Respir J, 2017, 50: 1700889.
7	Hoeper M, Pittrow D, Opitz C, et al. Risk assessment in pulmonary arterial hypertension[J]. Eur Respir J, 2018, 51: 1702606.
8	Machado RD, et al. Pulmonary arterial hypertension: a current perspective on established and emerging molecular genetic defects[J]. Hum. Mutat, 2015, 36: 1113-1127.
9	韩燕，杨振文，于铁链，等. 1.5T MRI评估肺动脉高压患者右心功能及肺动脉血液动力学[J]. 中国肺癌杂志，2012, 15(8): 471-475.
10	Hudsmith LE, Peteesen SE, Francis JM, et al. normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging[J]. J Cardiovasc Magn Reson, 2005, 7(5): 775-782.
11	云娟，何建国. 肺动脉高压右心室功能障碍的治疗进展[J]. 中华心血管病杂志，2011, 39(10): 967-969.
12	Chun HJ, Bonnet S, Chan SY. Translational advances in the field of pulmonary hypertension. Translating microrna biology in pulmonary hypertension. It will take more than "miR" words[J]. Am J Respir Crit Care Med, 2017, 195: 167-178.
13	Prior DL, Adams H, Williams TJ. Update on pharmacotherapy for pulmonary hypertension[J]. Med J Aust, 2016, 205: 271-276.
14	Hadinnapola C, et al. Phenotypic characterization of EIF2AK4 mutation carriers in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension[J]. Circulation, 2017, 136: 2022-2033.
15	Vonk Noordegraaf A, Chin KM, Haddad F, et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update[J]. Eur Respir J, 2019, 53: 1801900.
16	Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension[J]. Eur Heart J, 2018, 39: 4175-4181.
17	Weatherald J, Sitbon O, Humbert M. Validation of a risk assessment instrument for pulmonary arterial hypertension[J]. Eur Heart J, 2018, 38: 4182-4185.
18	Nazzareno Galiè，Richard N. Channick, Robert P, et al. Frantz.Risk stratification and medical therapy of pulmonary arterial hypertension[J]. Eur Respir J, 2019, 53(1): 1801889.
19	Hoeper M, Pittrow D, Opitz C, et al. Risk assessment in pulmonary arterial hypertension[J]. Eur Respir J, 2018, 51: 1702606.
20	Keusch S, Turk A, Saxer S, et al. Rehabilitation in patients with pulmonary arterial hypertension[J]. Swiss Med Wkly, 2017, 147: w14462.
21	Sitbon O, Sattler C, Bertoletti L, et al. Initial dual oral combination therapy in pulmonary arterial hypertension[J]. Eur Respir J, 2016, 47: 1727-1736.
22	Sofer A, Ryan MJ, Tedford RJ, et al. A systematic review of transition studies of pulmonary arterial hypertension specific medications[J]. Pulm Circ, 2017, 7: 326-338.
23	Maceira AM, Prasad SK, Khan M, et al. Reference right ventricular systolic and diastolic function normalized to age，gender and body surface area from steady-state free precession cardiovascular magnetic resonance[J]. Eur Heart J, 2006, 27(23): 2879-2888.
24	Long W, Wang J, Yang J, et al. Naturally-Derived PHA-L Protein Nanoparticle as a Radioprotector Through Activation of Toll-Like Receptor 5[J]. J Biomed Nanotechnol, 2019, 15(1): 62-76.
25	Frantz RP, Farber HW, Badesch DB, et al. Baseline and serial brain natriuretic peptide level predicts 5-year overall survival in patients with pulmonary arterial hypertension: data from the REVEAL Registry[J]. Chest, 2018, 154: 126-135.
26	Galiè N, Jansa P, Pulido T, et al. SERAPHIN haemodynamic substudy：the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension[J]. Eur Heart J, 2017, 38: 1147-1155.
27	Evans JD, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis[J]. Lancet Respir Med, 2016, 4: 129-137.
28	Chen CW, Hu S, Tsui KH, et al. Anti-inflammatory Effects of Gossypol on Human Lymphocytic Jurkat Cells via Regulation of MAPK Signaling and Cell Cycle[J]. Inflammation, 2018, 41(6): 2265-2274.
29	Butt FI, Muhammad N, Hamid A, et al. Recent progress in the utilization of biosynthesized polyhydroxyalkanoates for biomedical applications-Review.[J]. Int J Biolog Macromol, 2018, 120 (Pt A): 1294-1305.
30	Schmidt JF, Wissmann L, Manka R, et al. Iterative k-t principal component analysis with nonrigid motion correction for dynamic three-dimensional cardiac perfusion imaging[J]. Magn Reson Med, 2014, 72(1): 68-79.
31	Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension：The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertendion of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS)Endorsed by: Association for European Paediatric and Congenital(AEPC), International Society for Heart and Lung Transplantation(ISHLT)[J]. Eur Respir J, 2015, 46: 903-975.
32	McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension[J]. J Am Coll Cardiol, 2013, 62(25 Suppl)：D73-D81.

组　别	例数	MPA/T	RVW/T	RPA/T	LPA/T
观察组	25	1.22±0.11^a	0.50±0.08P^a	0.83±0.06^a	0.85±0.07^a
对照组	10	0.66±0.02	0.31±0.02	0.48±0.03	0.53±0.02

组　别	例数	MPA/T	RVW/T	RPA/T	LPA/T
观察组	25	1.22±0.11^a	0.50±0.08P^a	0.83±0.06^a	0.85±0.07^a
对照组	10	0.66±0.02	0.31±0.02	0.48±0.03	0.53±0.02

组　别	例数	PASP(mmHg)	PAMP(mmHg)	PVR(wood)
观察组	25	89.48±24.32^a	40.04±10.99^a	11.33±5.25^a
对照组	10	42.8±11.29	10.6± 1.57	1.21± 0.44

组　别	例数	PASP(mmHg)	PAMP(mmHg)	PVR(wood)
观察组	25	89.48±24.32^a	40.04±10.99^a	11.33±5.25^a
对照组	10	42.8±11.29	10.6± 1.57	1.21± 0.44

组　别	PASP		PAMP		PVR
组　别	r值	P值	r值	P值	r值	P值
MAP/T	0.802	<0.01	0.915	<0.01	0.816	<0.01
RAP/T	0.795	<0.01	0.852	<0.01	0.806	>0.01
RVW/T	0.78	<0.01	0.904	<0.01	0.802	<0.01

Please choose a citation manager

Content to export